https://orcid.org/0000-0002-6758-3074
References
- Horna P, Nowakowski G, Endell J, et al. Comparative assessment of surface CD19 and CD20 expression on B-cell lymphomas from clinical biopsies: implications for targeted therapies. Blood. 2019;134(Suppl. 1):5345.
- Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978–988.
- Novartis Pharmaceuticals Corporation. KYMRIAHTM (tisagenlecleucel) suspension for intravenous infusion. NJ: Novartis Pharmaceuticals Corporation, East Hanover, 2020.
- Kite Pharma Inc. YESCARTA® (axicabtagene ciloleucel) suspension for intravenous infusion. Santa Monica, CA: Kite Pharma, Inc., 2021.
- MONJUVI (tafasitamab-cxix) for injection, for intravenous use. MorphoSys US, Inc., Boston, MA, 2020.
- Thapa B, Caimi PF, Ardeshna KM, et al. CD19 antibody–drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv. 2020;4(16):3850–3852.
- Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J. 2016;14:357–362.
- Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
- Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282–1295.
- Fischer J, Paret C, El Malki K, et al. CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. J Immunother. 2017;40(5):187–195.
- Pillai V, Muralidharan K, Meng W, et al. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 2019;3(22):3539–3549.
- Upadhyay R, Boiarsky J, Pantsulaia G, et al. A critical role for fas-mediated off-target tumor killing in T-cell immunotherapy. Cancer Discov. 2020;11:599–613.
- Kuruvilla J. Developing anti-CD19 antibody-based combinations in lymphoma. Lancet Oncol. 2020;21(7):870–872.
- Oliai C, de Vos S. Case report: sustained remission achieved from anti-CD19 CAR T cell therapy despite prior treatment with anti-CD19 antibody tafasitamab (MOR208) in a patient with relapsed and refractory diffuse large B-cell lymphoma. Blood. 2019;134(Suppl. 1):5360.
- Asnani M, Hayer KE, Naqvi AS, et al. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia. 2020;34(4):1202–1207.